Artigo Revisado por pares

Modafinil treatment of pramipexole-associated somnolence

2000; Wiley; Volume: 15; Issue: 6 Linguagem: Inglês

10.1002/1531-8257(200011)15

ISSN

1531-8257

Autores

R. Hauser, Mervat Wahba, Theresa Zesiewicz, William M. Anderson,

Tópico(s)

Neurological disorders and treatments

Resumo

Movement DisordersVolume 15, Issue 6 p. 1269-1271 Clinical/Scientific Notes Modafinil treatment of pramipexole-associated somnolence Robert A. Hauser MD, Corresponding Author Robert A. Hauser MD Departments of Neurology, Pharmacology and Experimental Therapeutics, and Medicine, University of South Florida, Tampa General Hospital, Tampa, Florida, U.S.A.Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606, U.S.A.Search for more papers by this authorMervat N. Wahba MD, Mervat N. Wahba MD Department of Neurology, University of South Florida, Tampa General Hospital, Tampa, Florida, U.S.A.Search for more papers by this authorTheresa A. Zesiewicz MD, Theresa A. Zesiewicz MD Department of Neurology, University of South Florida, Tampa General Hospital, Tampa, Florida, U.S.A.Search for more papers by this authorW. McDowell Anderson MD, W. McDowell Anderson MD Department of Medicine, University of South Florida, Tampa General Hospital, Tampa, Florida, U.S.A.Search for more papers by this author Robert A. Hauser MD, Corresponding Author Robert A. Hauser MD Departments of Neurology, Pharmacology and Experimental Therapeutics, and Medicine, University of South Florida, Tampa General Hospital, Tampa, Florida, U.S.A.Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606, U.S.A.Search for more papers by this authorMervat N. Wahba MD, Mervat N. Wahba MD Department of Neurology, University of South Florida, Tampa General Hospital, Tampa, Florida, U.S.A.Search for more papers by this authorTheresa A. Zesiewicz MD, Theresa A. Zesiewicz MD Department of Neurology, University of South Florida, Tampa General Hospital, Tampa, Florida, U.S.A.Search for more papers by this authorW. McDowell Anderson MD, W. McDowell Anderson MD Department of Medicine, University of South Florida, Tampa General Hospital, Tampa, Florida, U.S.A.Search for more papers by this author First published: 17 January 2001 https://doi.org/10.1002/1531-8257(200011)15:6 3.0.CO;2-RCitations: 39AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 1992; 215: 161–170. 10.1016/0014-2999(92)90024-X CASPubMedWeb of Science®Google Scholar 2Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3, and D4 receptors. Eur J Pharmacol 1995; 290: 29–36. 10.1016/0922-4106(95)90013-6 CASPubMedWeb of Science®Google Scholar 3 Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. JAMA 1997; 278: 125–130. PubMedWeb of Science®Google Scholar 4Shannon KM, Bennett JP, Friedman JH, for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997; 49: 724–728. 10.1212/WNL.49.3.724 CASPubMedWeb of Science®Google Scholar 5Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162–168. 10.1212/WNL.49.1.162 CASPubMedWeb of Science®Google Scholar 6Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908–1910. 10.1212/WNL.52.9.1908 CASPubMedWeb of Science®Google Scholar 7Hoehn MM. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole [Letter]. Neurology 2000; 54: 275. CASPubMedWeb of Science®Google Scholar 8Arnold G. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole [Letter]. Neurology 2000; 54: 275–276. CASPubMedWeb of Science®Google Scholar 9Frucht S, Rogers JD, Greene PE, Fahn S, Gordon MF. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole [Letter]. Neurology 2000; 54: 276–277. PubMedWeb of Science®Google Scholar 10Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord. 2000; 15: 658–663. 10.1002/1531-8257(200007)15:4 3.0.CO;2-N CASPubMedWeb of Science®Google Scholar 11Modafinil for narcolepsy. Med Lett Drugs Ther 1999; 41: 30–31. PubMedGoogle Scholar 12Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540–545. 10.1093/sleep/14.6.540 CASPubMedWeb of Science®Google Scholar 13 US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43: 88–97. 10.1002/ana.410430115 PubMedWeb of Science®Google Scholar 14Hauser RA, Anderson WMcD, Friedlander J, Zesiewicz TA, Gauger LL. Somnolence associated with pramipexole therapy in Parkinson's disease [Abstract]. Mov Disord 1997; 12: 845. Google Scholar 15Horne J, Reyner L. Vehicle accidents related to sleep: a review. Occup Environ Med 1999; 56: 289–294. 10.1136/oem.56.5.289 CASPubMedWeb of Science®Google Scholar 16Fry J. Treatment modalities for narcolepsy. Neurology 1998; 52(suppl 1): S43–S48. 10.1212/WNL.50.2_Suppl_1.S43 Google Scholar 17Hogan V. Pemoline (Cylert): market withdrawal. CMAJ 2000; 162: 106. CASPubMedWeb of Science®Google Scholar Citing Literature Volume15, Issue6November 2000Pages 1269-1271 ReferencesRelatedInformation

Referência(s)
Altmetric
PlumX